×

Important OPT Congress Update

In light of evolving updates and concerns around the coronavirus, we’ve made the difficult decision to postpone the OPT Congress. Postponing provides us the opportunity to deliver the quality event that you expect from CHI, and a safe environment for our attendees, speakers, sponsors, exhibitors, and staff.

The OPT Congress represented a great opportunity to bring this ecosystem together, and advance the field. We are so disappointed to have to make this call, but feel it is the best way to move forward. We are actively working with local venues to find alternative dates, and will be reaching out to event speakers, sponsors and attendees once we know more.

COVID-19 Updates & FAQ


Keynote Speakers Include

Brett Monia, PhD
CEO, Ionis Pharmaceuticals

Edward Kaye, MD
CEO, Stoke Therapeutics

Amy Simon, MD
Executive Director, Clinical Research, Alnylam Pharmaceuticals

Dmitry Samarsky, PhD
CTO, Sirnaomics

Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi; Scientific Managing Director, COMPACT Consortium

Marvin Caruthers, PhD
Distinguished Professor, University of Colorado

Phil Baran, PhD
Professor, Department of Chemistry, Scripps Research

Peter Hagedorn
Senior Principal Scientist and Team Leader of Bioinformatics and RNA Biology, Roche Innovation Center Copenhagen

Melissa Marschel
Director, Regulatory Affairs CMC, Alnylam Pharmaceuticals

Kerry Benenato, PhD
Senior Director, Discovery Chemistry, Moderna

Roumen Radinov, PhD
Director Process Chemistry, Alnylam Pharmaceuticals

David Corey, PhD
Professor, Department of Pharmacology, UT Southwestern



With thanks to our Executive Advisory Board

Dmitry Samarsky, PhD
CTO, Sirnaomics

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Arthur Levin, PhD
Executive Vice President, Research and Development, Avidity Biosciences

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD
Senior Director, R&D Alliance Management, Sanofi


Join us at the 5th Annual Oligonucleotide & Precision Therapeutics Congress

Bringing together leading discovery scientists, developers, CMC experts, regulatory specialists and technology providers, OPT Congress provides a unique opportunity to discuss advances in next-generation oligonucleotide therapies throughout the drug development process. Attend in 2020 to optimize your drug design, delivery and performance, accelerate time to market and achieve commercial success. Based on the resounding success of last year’s inaugural 2-day program dedicated to Oligonucleotide CMC & Regulatory Strategies we will once again be adding this content to complement our established Oligonucleotide Discovery and Delivery conference. In addition, we deliver two in-depth symposiums focusing on Rare Disease Drug Development and NEW for 2020: AI in Drug Discovery and Development.

65%
of Attendees
from Biotech
15%
of Attendees
from Pharma
130+
Unique
Organizations
10+
Hours of
Networking





Premier Sponsor

Oligo-Factory